---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-058996"
form_type: "8-K"
ticker: "KOD"
cik: "0001468748"
company_name: "Kodiak Sciences Inc."
filed_at: "2023-11-06T23:59:59+00:00"
generated_at: "2026-06-08T19:41:24.814478+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Kodiak Phase 3 GLOW NPDR study meets primary endpoint; plans to resume tarcocimab

## Summary
- GLOW met primary endpoint: 41.1% vs 1.4% achieved >=2-step DRSS improvement (p<0.0001).
- Sight-threatening complications risk reduced 89%: 2.3% vs 21.0% (p<0.0001).
- DME development risk reduced 95%: 0.7% tarcocimab vs 13.7% sham.
- Kodiak pauses then resumes tarcocimab; plans one additional pivotal study for single BLA for wAMD, RVO, NPDR.
- Serious ocular adverse events and intraocular inflammation rates similar between groups.

## SEC filing metadata
- accession: 0000950170-23-058996
- form_type: 8-K
- ticker: KOD
- cik: 0001468748
- company_name: Kodiak Sciences Inc.
- filed_at: 2023-11-06T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1468748/000095017023058996/0000950170-23-058996-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1468748/000095017023058996/kod-20231106.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-058996
- JSON: https://secwatch.observer/filing/0000950170-23-058996.json
- Plain text: https://secwatch.observer/filing/0000950170-23-058996.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.